Dual antiplatelet therapy (DAPT) is the cornerstone of medical therapy in patients undergoing percutaneous coronary intervention. DAPT decreases the risk for ischemic events, including stent related complication as e.g. stent thrombosis, but increases the risk of bleeding. Current guidelines endorse DAPT after PCI for 6 months in stable patients, and 12 months in patients presenting with acute coronary syndrome (ACS), but with further options to adapt DAPT duration according to the patient's risk profile for ischemic or bleeding complications [1].Background The MitraClip procedure requires transseptal access of the left atrium with a 24F guiding sheath. We evaluated invasively whether a MitraClip induced iatrogenic atrial septal defect (IASD) leads to development of a relevant interatrial shunt and right ventricular overload. Methods A total of 69 patients who underwent a MitraClip procedure due to a severe mitral valve regurgitation (MVR) were included in the observational, retrospective cohort study. All pressures were directly measured throughout the procedure. Cardiac index (CI), systemic (Qs) and pulmonary (Qp) flow were calculated using the Fick method. Results Successful MitraClip implantation increased CI (2.5 ± 0.62 vs 3.05 ± 0.77 L/min/m2 ; P less then .0001), whereas SVR (1491 ± 474 vs 997 ± 301 dyn s/cm5 ; P less then .0001), PVR (226 ± 121 vs 188 ± 96 dyn/s/cm5 ; P = .04), PCWP (23 ± 6.1 vs 20 ± 4.7 mm Hg; P = .0031), PA pressure (33.6 ± 7.2 vs 31.9 ± 6.6 mm Hg; P = .1437) and LA pressure (21.5 ± 5.4 vs 18.7 ± 4.9 mm Hg; P less then .0001) all decreased. The effect on LA pressure was further enhanced by guiding catheter retrieval (14.4 ± 4.6 mm Hg; P less then .0001). At the end of the procedure, Qp (6.033 ± 1.3 L/min) exceeded Qs (5.537 ± 1.3 L/min) by 0.496 L/min leading to a QpQs ratio of 1.09 (P = .007). After 6 months, echocardiography revealed no changes in RV diameter (42.96 ± 6.95 mm vs 43.81 ± 7.67 mm; P = .62) and TAPSE (17.13 ± 3.33 mm vs 17.36 ± 3.24 mm; P = .48). Conclusion Our data show that the MitraClip procedure does not induce a relevant interatrial shunt or right ventricular overload. In fact, future studies will have to show whether the IASD may even be beneficial in selected patient populations by left atrial volume and pressure relief.TNFα is largely regarded as a proinflammatory cytokine, but several recent researches demonstrated that TNFα could possess immunoregulatory roles with potential to suppress antitumor immunity. Chronic hepatitis B virus (HBV) infection is a major risk factor of hepatocellular carcinoma (HCC) and HBV-specific CD8 T cells could exert antitumor roles in HCC patients. Here, we found that HBV-specific CD8 T cells, both in the peripheral blood and in the tumor microenvironment, were more enriched with TNFα-expressing cells than IFNγ-expressing cells. Compared to IFNγ-expressing HBV-specific CD8 T cells, TNFα-expressing HBV-specific CD8 T cells presented lower expression of inhibitory checkpoint molecules, including PD-1, TIM-3, and CTLA-4. HBV-specific CD8 T cells could mediate the lysis of autologous primary tumor cells and the inhibition of TNFα could further elevate their cytotoxic capacity. Subsequently, we demonstrated that TNFα inhibition in HBV-specific CD8 T cells could significantly increase granzyme B (GZMB) and perforin 1 (PRF1) expression while having no effect toward granzyme A (GZMA) expression. The addition of exogenous TNFα at low levels had no consistent effect on the expression of GZMA, GZMB, and PRF1, but at higher levels, exogenous TNFα significantly reduced GZMA, GZMB, and PRF1 expression. Overall, these results suggested that TNFα-expressing cells likely presented a deleterious role in HCC but were enriched in HBV-specific CD8 T cells.Objective The gold standard for diagnosing anti-NMDAR encephalitis is demonstration of the antibody in CSF. Clinical diagnostic criteria have been proposed for when this is not available in a timely manner which is evaluated, in this study, for a psychiatric population. Methods This study retrospectively assessed the proposed criteria in patients presenting to psychiatric services for the first time with known anti-NMDAR antibody status. Antibody-positive cases were derived from the literature (conception to December 2019) and a state-wide (Queensland, Australia) cohort. Antibody-negative cases were derived from a service-wide (Metro South, Queensland, Australia) cohort of psychiatric cases which underwent antibody testing for routine organic screening. Sensitivity and specificity were calculated at 1 week following admission and the point of discharge. Results The proposed criteria were applied to 641 cases (500 antibody-positive and 141 antibody-negative), demonstrating a sensitivity which increased from around 19% after 1 week to 49% by the point of discharge. Specificity was 100% at both time points. The mean average time to become positive using the proposed criteria was 19.5 days compared to 34.9 days for return of antibody testing. Conclusions High specificity of the proposed criteria, seen in this study, suggests that cases which are positive can be considered for expedited commencement of treatment. However, if clinical suspicion is high despite criteria being negative, it is essential to test CSF for anti-NMDAR antibody.Aims of study Although electroconvulsive therapy (ECT)-related anxiety is experienced by a significant proportion of patients, it remains understudied. Our aim was to study the course of ECT-related anxiety during ECT. Methods Seventy-four patients with unipolar or bipolar depression, referred for ECT, were included. ECT-related anxiety was assessed the morning before each ECT session using the ECT-related Anxiety Questionnaire (ERAQ). Results Female patients reported more anxiety than men (F(1,64.6) = 3.95, P = 0.05). https://www.selleckchem.com/products/ll37-human.html Patients with a psychotic depression were more anxious before the start of ECT (F(64.8) = 4.57, P = 0.04), but experienced a significant decrease in ECT-related anxiety (t(63.9) = -3.63, P = 0.0006), whereas patients with a non-psychotic depression remained stable on anxiety during their ECT course (t(63,9) = 0.76, P = 0.45). In addition, we found a significant correlation between the decrease of ECT-related anxiety and the decrease of depression-severity (r = 0.35; P = 0.04). Conclusion There are individual differences in ECT-related anxiety trajectories during ECT.